Using a stem cell-based signature to guide therapeutic selection in cancer.

ABSTRACT: Given the very substantial heterogeneity of most human cancers, it is likely that most cancer therapeutics will be active in only a small fraction of any population of patients. As such, the development of new therapeutics, coupled with methods to match a therapy with the individual patient, will be critical to achieving significant gains in disease outcome. One such opportunity is the use of expression signatures to identify key oncogenic phenotypes that can serve not only as biomarkers but also as a means of identifying therapeutic compounds that might specifically target these phenotypes. Given the potential importance of targeting tumors exhibiting a stem-like phenotype, we have developed an expression signature that reflects common biological aspects of various stem-like characteristi

SUBMITTER: Shats I 

PROVIDER: S-EPMC3049992 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature